Lead Product(s) : Cevidoplenib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Orphan Drug Designation to Cevidoplenib for ITP
Details : SKI-O-703 (cevidoplenib) is a SYK inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with immune thrombocytopenia.
Brand Name : SKI-O-703
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 21, 2024
Lead Product(s) : Cevidoplenib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cevidoplenib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib
Details : SKI-O-592 (cevidoplenib) binds to and inhibits SYK activity, blocking Fc receptor and BCR-mediated signaling in inflammatory cells. This leads to the inhibition of the related inflammatory responses and tissue damage. It is being developed for immune thr...
Brand Name : SKI-O-592
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2023
Lead Product(s) : Cevidoplenib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?